Clinical relevance of the lung resistance protein in diffuse large B-cell lymphomas

Clinical Cancer Research

Volumn 6, Issue 9, 2000, Pages 3417-3423

  Filipits, M ^a   Jaeger, U ^a   Simonitsch, I ^a   Chizzali Bonfadin, C ^a   Heinzl, H ^a   Pirker, R ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; LACTATE DEHYDROGENASE; LUNG RESISTANCE PROTEIN; METHOTREXATE; MONOCLONAL ANTIBODY; MULTIDRUG RESISTANCE PROTEIN; PREDNISONE; VINCRISTINE SULFATE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; FEMALE; HUMAN; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATP-BINDING CASSETTE TRANSPORTERS; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; ETOPOSIDE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LOMUSTINE; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; METHOTREXATE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PREDNIMUSTINE; PREDNISONE; REGRESSION ANALYSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VAULT RIBONUCLEOPROTEIN PARTICLES; VINCRISTINE;

EID: 0033817307     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma
2. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma
3. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: Updated results of the prospective study LNH87-2
4. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma
5. MDR1 gene expression and treatment outcome in acute myeloid leukemia
6. Multidrug resistance (mdr1) gene expression in adult acute leukemias: Correlations with treatment outcome and in vitro drug sensitivity
7. Clinical relevance of drug resistance genes in malignant diseases
8. The role of MDR-1 in refractory lymphoma
9. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil
10. Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance
11. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy
12. Expression of the multidrug resistance-associated protein gene in refractory lymphoma: Quantitation by a validated polymerase chain reaction assay
13. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma
14. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas
15. Disrupted p53 function as predictor of treatment failure and poor prognosis in B- and T-cell non-Hodgkin's lymphoma
16. p27(KIPI) Is abnormally expressed in diffuse large B-cell lymphomas and is associated with an adverse clinical outcome
17. 1 on resistance of tumor cells to anticancer agents
18. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance
19. The drug resistance-related protein LRP is the human major vault protein
20. Isolation and characterization of a novel ribonucleoprotein particle: Large structures contain a single species of small RNA
21. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines
22. Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells
23. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors
24. The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute-sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage
25. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
26. New approach to classifying non-Hod-gkin's lymphomas: Clinical features of the major histologic sub-types
27. World health organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the clinical advisory committee meeting, Airlie House, VA, November 1997
28. Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas
29. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma
30. Tissue distribution of the multidrug resistance protein
31. Nonparametric estimation from incomplete observations
32. Regression models and life tables
33. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia
34. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia
35. Overexpression of lung-resistance protein and increased P-glyco-protein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival
36. Drug resistance factors in acute myeloid leukemia: A comparative analysis
37. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein. P-glycoprotein expression, and drug resistance in childhood leukemia
38. Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma
39. Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma
40. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma
41. Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome
42. Immunohistochemical detection of multidrug resistance associated P-glycoprotein in tumour and stromal cells of human cancers
43. Expression of a multidrug resistance gene in human cancers
44. Immunohistochemical detection of the multidrug transport protein P170 in human normal tissues and malignant lymphomas
45. Immunohistochemical identification of P-glycoprotein in previously untreated, diffuse large cell and immunoblastic lymphomas
46. Expression of P-glycoprotein and anionic glutathione S-transferase genes in non-Hodgkin's lymphoma
47. Expression of P-glycoprotein and glutathione-S-transferase in recurrent lymphomas: The possible role of Epstein-Barr vires, immunophenotypes, and other predisposing factors
48. Expression of mdr-1 in refractory lymphoma: Quantitation by polymerase chain reaction and validation of the assay
49. + non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance
50. Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis
51. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma
52. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: A British National Lymphoma Investigation Study
53. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma
54. Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins